Log In
Print
BCIQ
Print
Print this Print this
 

GKI-399, TTP399

  Manage Alerts
Collapse Summary General Information
Company vTv Therapeutics LLC
DescriptionLiver-selective glucokinase (GCK; GK) activator
Molecular Target Glucokinase (GCK) (GK)
Mechanism of ActionGlucokinase activator
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,100.0M

$50.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today